Aarey Drugs & Pharmaceuticals Reports Mixed Financial Results Amid Operational Challenges in August 2025

Aarey Drugs & Pharmaceuticals has recently reported its financial results for the quarter ending June 2025, with the announcement made on August 13, 2025. The company, operating within the Pharmaceuticals & Biotechnology sector, has experienced notable shifts in its financial metrics during this period. The evaluation changes indicate that Aarey Drugs has seen a revision in its score, moving to -10 from -14 over the past three months. This adjustment reflects a complex financial landscape for the company. On a positive note, the Debtors Turnover Ratio has reached its highest level in the last five half-yearly periods, recorded at 3.66 times, suggesting that the company has been effective in settling its debtors more swiftly. Conversely, the financial results also highlight challenges. The Profit After Tax (PAT) for the latest six months stands at Rs 1.84 crore, showing a significant decline year on year. Additionally, net sales for the quarter have fallen to Rs 102.21 crore, marking the lowest figure in the last five quarters. Furthermore, a substantial portion of the company's income is derived from non-operating activities, raising concerns about the sustainability of its business model. For more insights, Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.